<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="39867">Valproic acid</z:chebi> (VPA), an inhibitor of <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylases, inhibits the growth of <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells and induces their differentiation in vitro </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, VPA in combination with two differentiating agents, <z:chebi fb="0" ids="6067">13-cis retinoic acid</z:chebi> and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Eight patients had to discontinue treatment before week 16 due to toxicity </plain></SENT>
<SENT sid="3" pm="."><plain>According to international working group criteria, three patients (16%) responded to treatment </plain></SENT>
<SENT sid="4" pm="."><plain>No correlation between VPA serum level, <z:chebi fb="0" ids="15358">histone</z:chebi> acetylation or clinical response was observed </plain></SENT>
</text></document>